[Back to Issue 4 ToC] [Back to Journal Contents] [Back to Biochemistry (Moscow) Home page]

Design of a Novel Interleukin-13 Antagonist from Analysis of Informational Structure

A. N. Nekrasov1*, L. E. Petrovskaya1, V. A. Toporova1, E. A. Kryukova1, A. V. Rodina2, E. Yu. Moskaleva2, and M. P. Kirpichnikov1

1Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, 117997 Moscow, Russia; fax: (495) 330-6983; E-mail: alexei_nekrasov@mail.ru

2Moscow Research Institute of Medical Ecology, Department of Health Care, Simferopolsky Bulvar 8, 117638 Moscow, Russia; fax: (496) 113-4827; E-mail: allrodina@yandex.ru

* To whom correspondence should be addressed.

Received August 6, 2008; Revision received October 14, 2008
Interleukin-13 (IL-13) is one of the cytokines involved in the development of Th2-type immune response. It plays an important role in the pathogenesis of asthma and other allergic diseases. Two deletion forms of IL-13 were constructed on a basis of informational structure analysis and expressed in E. coli cells. They were found to differ in ability to stimulate proliferation of TF-1 cell line. Deletion variant 146 (DV146) completely lacks such activity, whereas DV148 provides about 50% of the proliferation stimulation. The simultaneous addition of DV146 with full-length IL-13 suppresses proliferation depending on the concentration of the deletion form. Thus, the designed protein acts as an antagonist of IL-13.
KEY WORDS: ANIS method, informational structure, deletion variant, IL-13 antagonist, TF-1 proliferation

DOI: 10.1134/S0006297909040075